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Cell dosage is a limiting factor for cord blood transplantation
(CBT), especially for adult patients. Most CB banks practice red
cell depletion (RCD) techniques to save storage space, which incur
signiﬁcant nucleated cell loss after processing. One method to
maximize cell recovery and still reduce volume after processing is
to deplete plasma (PD), but not the red blood cells. Not washing
UCB (NW) after thawing also minimizes cell loss. A third strategy
is to employ double cords. A large racially diverse PD UCB
inventory of over 25,000 units is now available. An audited retro-
spective analysis was performed on all adult patients with malig-
nancies that have available engraftment and/or survival data, with
20 AML, 18 ALL, 12 CML, and 18 patients transplanted for other
malignant indications. Of these, 20 patients had standard risks
(29%), 34 patients (50%) with advanced risks and 14 risk status
unknown (21%). Patients were classiﬁed as adults in two different
ways: by age (16 years and older) and by weight (at least 50kg). By
age, there were 55 patients transplanted with 67 PD UCB units (27
double cords). By weight, there were 62 patients transplanted with
75 PD UCB units (31 double cords). The median age of patients of
the combined group was 29 years old (range 9.6-59); median
weight 62 kg (range 39-112); male 55%. Transplant characteristics
indicated a median # HLA ABDR matches of 4.0; median pre-
freeze TNC dose 2.9  107/kg; median post-thaw TNC dose as
reported by TC 2.5 107/kg; median pre-freeze CD34 dose 0.9
105/kg; transplants outside of U.S. 24%; double unit transplant
47%; non-myeloablative 29%. Fifty-two percent of the trans-
planted UCB were washed post-thaw (W) and 41% were infused
without post-thaw wash (NW), with 7% of the units without
available post-thaw data. Median follow-up time was 111.5 days
(range 2-1263 days). Kaplan-Meier estimates were used for en-
graftment, relapse, TRM, OS and Relapse Free Survival (RFS)
rates with all patients who expired before engraftment counted as
engraftment failures. Patients 16 years or older were also stratiﬁed
by risk status. Results are summarized below. These results dem-
onstrate that HSCT using unrelated PD UCB can be performed
safely and effectively in adult patients with malignancies.
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Hematopoietic stem cells (HSC) interact with stromal cells, os-
teoblasts and matrix proteins in the hematopoietic niche. This
interaction plays an important role in HSC trafﬁcking, prolifera-
tion and differentiation. Signiﬁcant data support the roles of both
the SDF-1/CXCR4 and the VCAM1-VLA-4 axes in stem cell
homing and mobilization. Little is known regarding the impact of
these ligand-receptor pairs in leukemia cell trafﬁcking. We hy-
pothesize that both CXCR4VLA-4 play important roles in leu-
kemia cell trafﬁcking while also transmitting protective signals
enhancing survival and resistance to chemotherapy and that their
blockade may enhance the sensitivity of AML to chemotherapy.
To evaluate this we developed a model of human APL in which
the PML-RAR
 is “knocked-into” the mouse cathepsin G locus
allowing for expression in the promyelocyte compartment. APL
tumors generated from these CGPR/ mice were transduced with
retroviral contructs containing the Click Beetle Red/eGFP optical
imaging reporter gene for tracking APL cells using biolumines-
cence imaging (BLI). Unlike other AML cell lines tested these
APL cells rapidly migrated to the BM (femurs and spine) by day4
followed by egress to the spleen (11) then to the peripheral blood
and death (18-22). The administration of AMD3100, a CXCR4
antagonist, induced a rapid mobilization of normal HSC and leu-
kemia cells from the BM into peripheral blood (PB). The addition
of AMD3100 1 hour before and 3 hours after either ara-C or
daunorubicin on day 11 resulted in signiﬁcant improvement in
overall survival and decrease in total photon emission compared to
those mice treated with chemotherapy alone.
We have extended these studies using an inhibitor of VLA-4
(AMD15057) and have shown that this molecule directly mobilizes
HSC and APL cells from the BM into the peripheral blood within
minutes and when administered with AMD3100 has a synergistic
effect on both HSC and APL mobilization. Current studies are
aimed at looking at in vitro and in vivo effects of blocking CXCR4
and VLA-4 axes on normal HSC and leukemia cell mobilization
and what effects these events might have on the sensitivity of
normal and leukemic stem cells to chemotherapy and other geno-
toxic stresses.
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MRD based on leukemia-speciﬁc immunoglobulin (Ig) and
T-cell receptor (TCR) gene rearrangements has become a tool
inﬂuencing clinical decisions in many therapeutic trials for
childhood acute lymphoblastic leukemia (ALL). It has been
repeatedly documented, that positive MRD pre-transplant is
highly predictive for post-transplant relapse of ALL, but we
have failed to document the same value in 14 children with
PhALL which at our unit underwent allogeneic stem cell
transplantation (SCT). The presence of BCR/ABL fusion gene
offers a possibility of the fusion transcript detection - a faster
and cheaper alternative to Ig/TCR-based MRD monitoring. Up
to now, no direct comparison based on a sufﬁcient number of
samples has been done. We have analyzed 350 follow-up sam-
ples from 16 children (aged 4-17 years) with BCR/ABL-positive
ALL by Ig/TCR-based RQ-PCR and by RT-RQ-PCR for
BCR/ABL transcripts. All children expressed m-BCR/ABL
transcript at the time of diagnosis; 3 of 16 children expressed
both m-BCR/ABL and M-BCR/ABL transcripts representing
the p190 and p210 variant of BCR/ABL protein, respectively.
For further analysis we used the higher value of m- and M-BCR/
ABL as the BCR/ABL MRD level. For the comparison with
Ig/TCR-based method, MRD levels in follow-up samples were
related to the expression levels in diagnostic samples, which
were set to 1. In total, 133 (38%) and 127 (36%) samples were
negative and positive by both methods, respectively. The quan-
titative levels differed by more than 1 log in 46 (36%) double-
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